Cargando…
CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting
Due to the concern of fratricide, clinical development of CAR T cells for the therapy of T cell malignancies lags behind that for B cell malignancies. Attempts are being made to revise T cell biomarkers so that the re-engineered CAR T cells can target T cell malignancies. CD3 and CD7 are the two pan...
Autores principales: | Huang, Qiusha, Zhang, Xiao-hui, Liu, Delong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985840/ https://www.ncbi.nlm.nih.gov/pubmed/36871011 http://dx.doi.org/10.1186/s13045-023-01406-8 |
Ejemplares similares
-
Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
por: Cao, Yang, et al.
Publicado: (2023) -
Targeted treatment of T-cell acute lymphoblastic leukemia: latest updates from the 2022 ASH Annual Meeting
por: Xu, Jieyu, et al.
Publicado: (2023) -
Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting
por: DiNardo, Katherine W., et al.
Publicado: (2023) -
Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting
por: Wang, Chaoyu, et al.
Publicado: (2023) -
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
por: Gong, Xubo, et al.
Publicado: (2023)